November 21, 2024
Lan Zhang, Juan Zhan, Meng Qiao, Xuefei Yan, Jian Ding, Fei Chen, Xiaoyu An, WenQing Yang, and Qian Shi
Despite the unprecedented success of immune checkpoint antibodies for a variety of cancer types, a lack of immunocompetent preclinical mouse models remains a major challenge for the development of novel immunotherapeutics.
Different strategies to humanize immunodeficient mouse model systems have been reported, including replenishment with human HSC or PBMC, as well as the development of chimeric models harboring human immune checkpoint targets in immunocompetent mice.
CrownBio has successfully established a number of human PBMC-humanized xenograft models (MiXeno), which require optimization.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-05-22
2021-10-29
landing_page
PDX/Databases